Associated Papers
[Expert consensus on the diagnosis and treatment of advanced non-small cell lung cancer with EGFR PACC mutations (2025 edition)].
Unknown Author
Zhonghua Zhong Liu Za Zhi [chinese Journal of Oncology], 2025
Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations.
Wells L et al.
Current Treatment Options in Oncology, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.
Yang JC et al.
Frontiers in Oncology, 2022
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Robichaux JP et al.
Nature, 2021
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations.
Ikemura S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2019
31043566 (PubMed )
Supplement: pnas.1819430116.sapp.pdf
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.
Zou B et al.
Scientific Reports, 2017
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Sie D et al.
Cellular Oncology (dordrecht, Netherlands), 2014
Select a paper to view details